Myeloid Leukemia clinical trials

Explore recruiting myeloid leukemia clinical trials.

Recruiting myeloid leukemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Myeloid Leukemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of MK‑0482 in Participants with Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

VEN-R DASA-IPC 2022-067 Evaluation of DASATINIB monotherapy in acute myeloid leukemia patients refractory to VENETOCLAX-AZACITIDINE

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Prospective Phase II Clinical Trial Evaluating the Efficacy and the Safety of Tyrosine Kinase Inhibitors Withdrawal After a Previous Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia in Deep Molecular Remission

Czechia

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML

Czechia, Netherlands, France, Denmark, Spain, Portugal +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3b, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other luspatercept (ACE-536, also known as BMS 986346) clinical trials.

Greece, Italy, Germany, Spain, France, Bulgaria +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Myeloid Leukemia trials by city

Myeloid Leukemia in Toronto Myeloid Leukemia in Vancouver Myeloid Leukemia in Montreal Myeloid Leukemia in Calgary Myeloid Leukemia in Edmonton Myeloid Leukemia in Ottawa Myeloid Leukemia in Winnipeg Myeloid Leukemia in Quebec City Myeloid Leukemia in Hamilton Myeloid Leukemia in Kitchener Myeloid Leukemia in London Myeloid Leukemia in Halifax Myeloid Leukemia in New York Myeloid Leukemia in Los Angeles Myeloid Leukemia in Chicago Myeloid Leukemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease